OpenLB
Open Library of Bioscience
Advanced Search
Antibiotics (Basel, Switzerland)
Jan 11, 2024;13 (1):

New Antimicrobial Strategies to Treat Multi-Drug Resistant Infections Caused by Gram-Negatives in Cystic Fibrosis.

Viola Camilla Scoffone, Giulia Barbieri, Samuele Irudal, Gabriele Trespidi, Silvia Buroni
Author Information
  1. Viola Camilla Scoffone: Department of Biology and Biotechnology "Lazzaro Spallanzani", University of Pavia, 27100 Pavia, Italy.
  2. Giulia Barbieri: Department of Biology and Biotechnology "Lazzaro Spallanzani", University of Pavia, 27100 Pavia, Italy. ORCID
  3. Samuele Irudal: Department of Biology and Biotechnology "Lazzaro Spallanzani", University of Pavia, 27100 Pavia, Italy. ORCID
  4. Gabriele Trespidi: Department of Biology and Biotechnology "Lazzaro Spallanzani", University of Pavia, 27100 Pavia, Italy. ORCID
  5. Silvia Buroni: Department of Biology and Biotechnology "Lazzaro Spallanzani", University of Pavia, 27100 Pavia, Italy. ORCID
PMID: 38247630 DOI: 10.3390/antibiotics13010071

Abstract

People with Cystic Fibrosis (CF) suffer from recurrent bacterial Infections which induce inflammation, lung tissue damage and failure of the respiratory system. Prolonged exposure to combinatorial antibiotic therapies triggers the appearance of multi-drug resistant (MDR) bacteria. The development of alternative antimicrobial strategies may provide a way to mitigate antimicrobial resistance. Here we discuss different alternative approaches to the use of classic antibiotics: anti-virulence and anti-biofilm compounds which exert a low selective pressure; phage therapies that represent an alternative strategy with a high therapeutic potential; new methods helping antibiotics activity such as adjuvants; and antimicrobial peptides and nanoparticle formulations. Their mechanisms and in vitro and in vivo efficacy are described, in order to figure out a complete landscape of new alternative approaches to fight MDR Gram-negative CF pathogens.

Keywords

Gram-negative pathogens adjuvants alternative antimicrobial strategies anti-virulence compounds antimicrobial peptides cystic fibrosis nanoparticles phage therapy

References

  1. Arch Microbiol. 2023 Nov 8;205(12):374 [PMID: 37935892]
  2. Eur J Pharm Biopharm. 2019 Sep;142:543-552 [PMID: 31398437]
  3. Nanomedicine. 2020 Oct;29:102259 [PMID: 32619707]
  4. Antibiotics (Basel). 2021 Jul 15;10(7): [PMID: 34356783]
  5. Amino Acids. 2019 Mar;51(3):383-393 [PMID: 30392097]
  6. Genes (Basel). 2020 May 11;11(5): [PMID: 32403302]
  7. Pharmaceutics. 2022 Dec 20;15(1): [PMID: 36678633]
  8. Appl Microbiol Biotechnol. 2019 Jul;103(14):5821-5830 [PMID: 31101943]
  9. Molecules. 2022 Mar 06;27(5): [PMID: 35268822]
  10. Eur Respir Rev. 2023 Jan 11;32(167): [PMID: 36631132]
  11. Biochem Mol Biol Int. 1998 May;44(6):1119-26 [PMID: 9623765]
  12. Bioorg Med Chem. 2021 May 15;38:116110 [PMID: 33831695]
  13. FASEB J. 2010 Apr;24(4):1015-22 [PMID: 19917670]
  14. J Antimicrob Chemother. 2016 Jan;71(1):181-8 [PMID: 26433781]
  15. ACS Infect Dis. 2019 Jul 12;5(7):1129-1138 [PMID: 31016966]
  16. Curr Microbiol. 2022 May 5;79(6):180 [PMID: 35508743]
  17. Viruses. 2023 Jul 30;15(8): [PMID: 37632008]
  18. Front Microbiol. 2022 Jul 05;13:906961 [PMID: 35865914]
  19. Future Med Chem. 2019 Jul;11(13):1565-1582 [PMID: 31469336]
  20. ChemMedChem. 2021 Feb 4;16(3):513-523 [PMID: 33090655]
  21. Expert Rev Anti Infect Ther. 2023 Feb;21(2):213-223 [PMID: 36625029]
  22. Antimicrob Agents Chemother. 2018 Mar 27;62(4): [PMID: 29437631]
  23. Molecules. 2021 Nov 02;26(21): [PMID: 34771051]
  24. Eur J Biochem. 2002 Feb;269(3):923-32 [PMID: 11846794]
  25. Microb Biotechnol. 2018 Nov;11(6):1037-1047 [PMID: 29635772]
  26. Microbiology (Reading). 2022 Mar;168(3): [PMID: 35358034]
  27. Pharmaceuticals (Basel). 2023 May 31;16(6): [PMID: 37375770]
  28. Eur J Med Chem. 2019 Dec 1;183:111708 [PMID: 31550659]
  29. Nanomedicine. 2020 Jan;23:102113 [PMID: 31669084]
  30. Res Microbiol. 2018 Nov;169(9):540-542 [PMID: 29777836]
  31. Infect Drug Resist. 2018 Oct 11;11:1767-1782 [PMID: 30349334]
  32. Chem Rev. 2019 May 8;119(9):6040-6085 [PMID: 30624911]
  33. Microbiol Spectr. 2022 Oct 26;10(5):e0160222 [PMID: 35972246]
  34. Biochim Biophys Acta Biomembr. 2017 Dec;1859(12):2327-2339 [PMID: 28912103]
  35. PLoS Pathog. 2021 Sep 3;17(9):e1009909 [PMID: 34478485]
  36. J Investig Med High Impact Case Rep. 2023 Jan-Dec;11:23247096231188243 [PMID: 37515541]
  37. Int J Pharm. 2021 Dec 15;610:121160 [PMID: 34624446]
  38. Int J Pharm. 2020 Aug 30;586:119548 [PMID: 32565286]
  39. Antimicrob Agents Chemother. 2019 Mar 27;63(4): [PMID: 30670425]
  40. Antimicrob Agents Chemother. 2016 Apr 22;60(5):2813-21 [PMID: 26902766]
  41. Proc Natl Acad Sci U S A. 2018 May 29;115(22):E5125-E5134 [PMID: 29760087]
  42. J Med Chem. 2023 Nov 9;66(21):14735-14754 [PMID: 37874867]
  43. J Clin Med. 2018 Jun 22;7(7): [PMID: 29932132]
  44. Commun Biol. 2022 Aug 25;5(1):871 [PMID: 36008485]
  45. Molecules. 2023 Mar 29;28(7): [PMID: 37049808]
  46. Peptides. 2011 Sep;32(9):1807-14 [PMID: 21849157]
  47. Front Cell Infect Microbiol. 2019 Mar 11;9:49 [PMID: 30915278]
  48. Eur J Med Chem. 2019 Jul 15;174:16-32 [PMID: 31022550]
  49. mSphere. 2018 Dec 12;3(6): [PMID: 30541778]
  50. Front Microbiol. 2020 Jun 24;11:1358 [PMID: 32670234]
  51. J Clin Microbiol. 2019 Jul 26;57(8): [PMID: 31167848]
  52. Viruses. 2021 Jun 29;13(7): [PMID: 34209836]
  53. Front Microbiol. 2020 Aug 26;11:1947 [PMID: 32983005]
  54. Antimicrob Agents Chemother. 2015 Apr;59(4):2315-27 [PMID: 25645838]
  55. Clin Microbiol Infect. 2019 May;25(5):629.e1-629.e6 [PMID: 30107283]
  56. Crit Rev Biotechnol. 2020 Nov;40(7):978-992 [PMID: 32781848]
  57. J Med Chem. 2019 Oct 24;62(20):9103-9115 [PMID: 31557020]
  58. J Inorg Biochem. 2022 May;230:111751 [PMID: 35151101]
  59. Sci Adv. 2020 May 01;6(18):eaay6817 [PMID: 32426473]
  60. Virulence. 2020 Dec;11(1):652-668 [PMID: 32423284]
  61. BMC Microbiol. 2023 Jan 5;23(1):2 [PMID: 36600213]
  62. Front Mol Biosci. 2023 Oct 16;10:1264773 [PMID: 37908228]
  63. Bioorg Chem. 2018 Oct;80:639-648 [PMID: 30053708]
  64. mSphere. 2021 Jun 16;:e0040121 [PMID: 34133200]
  65. Antimicrob Agents Chemother. 2019 Jun 24;63(7): [PMID: 31010858]
  66. Molecules. 2022 Aug 27;27(17): [PMID: 36080283]
  67. Proc Biol Sci. 2018 Mar 14;285(1874): [PMID: 29540517]
  68. Molecules. 2023 Sep 09;28(18): [PMID: 37764311]
  69. Sci Rep. 2022 Jun 18;12(1):10299 [PMID: 35717537]
  70. Curr Opin Microbiol. 2015 Oct;27:1-9 [PMID: 26042389]
  71. ACS Appl Mater Interfaces. 2021 Sep 15;13(36):42329-42343 [PMID: 34464076]
  72. Nat Rev Microbiol. 2016 Aug 11;14(9):576-88 [PMID: 27510864]
  73. FASEB J. 2020 Jan;34(1):192-207 [PMID: 31914681]
  74. Sci Rep. 2017 Aug 17;7(1):8548 [PMID: 28819175]
  75. Biomedicines. 2022 Jun 28;10(7): [PMID: 35884830]
  76. Antibiotics (Basel). 2022 Sep 20;11(10): [PMID: 36289935]
  77. Front Chem. 2017 Jun 19;5:40 [PMID: 28674688]
  78. Cells. 2019 Oct 07;8(10): [PMID: 31591302]
  79. Pharmaceuticals (Basel). 2022 Feb 11;15(2): [PMID: 35215328]
  80. Virus Res. 2022 Jun;314:198751 [PMID: 35307481]
  81. Appl Microbiol Biotechnol. 2020 Oct;104(20):8859-8869 [PMID: 32865612]
  82. Transpl Infect Dis. 2023 Apr;25(2):e14041 [PMID: 36864824]
  83. Chem Biol. 2013 Oct 24;20(10):1286-95 [PMID: 24120333]
  84. Microbiol Spectr. 2023 Feb 14;11(1):e0403022 [PMID: 36700630]
  85. J Antimicrob Chemother. 2019 Sep 1;74(9):2640-2648 [PMID: 31139830]
  86. Small. 2021 Jun;17(24):e2100531 [PMID: 33978317]
  87. Microb Pathog. 2023 Dec;185:106433 [PMID: 37913826]
  88. Curr Microbiol. 2022 Nov 25;80(1):5 [PMID: 36434296]
  89. J Cyst Fibros. 2021 Mar;20(2):264-270 [PMID: 32482592]
  90. Int J Pharm. 2014 Dec 30;477(1-2):485-94 [PMID: 25445528]
  91. Antibiotics (Basel). 2021 Aug 26;10(9): [PMID: 34572625]
  92. Polymers (Basel). 2021 Aug 06;13(16): [PMID: 34451161]
  93. Molecules. 2021 Mar 10;26(6): [PMID: 33801847]
  94. Antimicrob Agents Chemother. 2014;58(2):978-85 [PMID: 24277028]
  95. Antimicrob Agents Chemother. 2013 Nov;57(11):5665-73 [PMID: 24002100]
  96. ACS Infect Dis. 2021 Apr 9;7(4):721-732 [PMID: 33689277]
  97. Trials. 2022 Dec 28;23(1):1057 [PMID: 36578069]
  98. Antibiotics (Basel). 2023 Mar 16;12(3): [PMID: 36978460]
  99. Trends Pharmacol Sci. 2017 May;38(5):473-488 [PMID: 28283200]
  100. Antimicrob Agents Chemother. 2021 Oct 18;65(11):e0133221 [PMID: 34370574]
  101. J Bacteriol. 2023 Oct 26;205(10):e0019623 [PMID: 37791751]
  102. Antimicrob Agents Chemother. 2017 Jul 25;61(8): [PMID: 28559270]
  103. Microorganisms. 2021 Feb 25;9(3): [PMID: 33668889]
  104. Curr Biol. 2016 Jan 11;26(1):R14-9 [PMID: 26766224]
  105. Microb Drug Resist. 2020 Oct;26(10):1133-1143 [PMID: 32364820]
  106. J Biol Chem. 2003 Nov 21;278(47):46590-5 [PMID: 12972419]
  107. J Med Chem. 2014 May 22;57(10):4263-72 [PMID: 24801877]
  108. iScience. 2022 May 10;25(6):104372 [PMID: 35620437]
  109. BMC Microbiol. 2019 Mar 8;19(1):54 [PMID: 30849936]
  110. J Chemother. 2021 Jul;33(4):216-227 [PMID: 32985386]
  111. Innate Immun. 2015 Jan;21(1):17-29 [PMID: 24345876]
  112. Pharmaceuticals (Basel). 2021 Nov 15;14(11): [PMID: 34832944]
  113. J Control Release. 2016 Oct 28;240:109-126 [PMID: 26571000]
  114. Antibiotics (Basel). 2023 Jan 20;12(2): [PMID: 36830128]
  115. Antibiotics (Basel). 2023 Feb 08;12(2): [PMID: 36830260]
  116. Virus Genes. 2021 Apr;57(2):205-216 [PMID: 33471272]
  117. Lancet Infect Dis. 2021 Mar;21(3):309-311 [PMID: 32949499]
  118. ACS Omega. 2023 Aug 01;8(32):29359-29373 [PMID: 37599980]
  119. ACS Infect Dis. 2023 Apr 14;9(4):864-885 [PMID: 36917096]
  120. Bioorg Chem. 2023 Jan;130:106266 [PMID: 36399865]
  121. ACS Infect Dis. 2022 May 13;8(5):1086-1097 [PMID: 35404568]
  122. Microbiol Spectr. 2023 Jun 15;11(3):e0443022 [PMID: 37195168]
  123. Semin Immunol. 2017 Dec;34:25-32 [PMID: 28985993]
  124. Front Microbiol. 2011 Jul 22;2:159 [PMID: 21811491]
  125. PLoS One. 2013 Nov 14;8(11):e79220 [PMID: 24244452]
  126. Front Microbiol. 2018 Aug 21;9:1952 [PMID: 30186266]
  127. ACS Infect Dis. 2020 Jun 12;6(6):1413-1426 [PMID: 32357292]
  128. Pediatr Pulmonol. 2019 Nov;54 Suppl 3:S84-S96 [PMID: 31715083]
  129. JAC Antimicrob Resist. 2023 Apr 18;5(2):dlad046 [PMID: 37082420]
  130. BMC Microbiol. 2011 Aug 31;11:195 [PMID: 21880144]
  131. Microbiol Res. 2024 Jan;278:127528 [PMID: 37918082]
  132. Biomed Res Int. 2018 Sep 10;2018:5810767 [PMID: 30276212]
  133. Antimicrob Agents Chemother. 2020 Jan 27;64(2): [PMID: 31767727]
  134. Sci Rep. 2023 Jun 1;13(1):8876 [PMID: 37264060]
  135. Sci Rep. 2016 Sep 01;6:32487 [PMID: 27580679]
  136. Int J Nanomedicine. 2020 Feb 17;15:1117-1128 [PMID: 32110011]
  137. Antibiotics (Basel). 2021 Sep 27;10(10): [PMID: 34680757]
  138. J Antimicrob Chemother. 2021 Sep 15;76(10):2578-2585 [PMID: 34283223]
  139. Microbiol Spectr. 2023 Mar 28;:e0451922 [PMID: 36975825]
  140. BMC Microbiol. 2012 Jul 23;12:145 [PMID: 22823964]
  141. Microbiol Spectr. 2022 Aug 31;10(4):e0178722 [PMID: 35856676]
  142. J Virol. 2021 Jan 20;95(8): [PMID: 33472935]
  143. Sci Rep. 2022 Jan 7;12(1):180 [PMID: 34996996]
  144. Antibiotics (Basel). 2023 Apr 10;12(4): [PMID: 37107097]
  145. ACS Infect Dis. 2018 Sep 14;4(9):1407-1422 [PMID: 30022668]
  146. Antimicrob Agents Chemother. 2001 Oct;45(10):2838-44 [PMID: 11557478]
  147. Int J Med Sci. 2018 Mar 28;15(6):617-627 [PMID: 29725253]
  148. Biomedicines. 2022 Nov 10;10(11): [PMID: 36359406]
  149. Antimicrob Agents Chemother. 2021 Mar 18;65(4): [PMID: 33495218]
  150. Front Cell Infect Microbiol. 2020 Aug 27;10:441 [PMID: 32974221]
  151. Pharm Res. 2018 Aug 9;35(10):187 [PMID: 30094660]
  152. BMC Evol Biol. 2010 Jun 03;10:164 [PMID: 20525265]
  153. Int J Mol Sci. 2021 Aug 19;22(16): [PMID: 34445641]
  154. Biomedicines. 2023 Jan 31;11(2): [PMID: 36830949]
  155. Antibiotics (Basel). 2022 Feb 28;11(3): [PMID: 35326782]
  156. Biomolecules. 2023 Aug 07;13(8): [PMID: 37627291]
  157. Bioorg Med Chem. 2020 Mar 1;28(5):115229 [PMID: 32033878]
  158. BMC Microbiol. 2010 May 12;10:140 [PMID: 20462423]
  159. Int J Mol Sci. 2019 Nov 14;20(22): [PMID: 31739573]
  160. J Antimicrob Chemother. 2022 Sep 30;77(10):2642-2649 [PMID: 35897129]
  161. Int J Pharm. 2019 May 30;563:30-42 [PMID: 30926526]
  162. Microbiol Resour Announc. 2021 May 20;10(20): [PMID: 34016684]
  163. Antibiotics (Basel). 2020 Mar 02;9(3): [PMID: 32131413]
  164. BioDrugs. 2003;17(4):233-40 [PMID: 12899640]
  165. Microb Pathog. 2023 Dec;185:106403 [PMID: 37879452]
  166. Mar Drugs. 2013 May 13;11(5):1534-52 [PMID: 23670533]
  167. Nat Biotechnol. 2005 Aug;23(8):1008-12 [PMID: 16041366]
  168. World J Microbiol Biotechnol. 2022 Aug 30;38(11):209 [PMID: 36040540]
  169. Microorganisms. 2021 Sep 21;9(9): [PMID: 34576896]
  170. Nat Rev Microbiol. 2012 Mar 16;10(4):243-54 [PMID: 22421877]
  171. Am J Rhinol Allergy. 2019 Mar;33(2):129-136 [PMID: 30585080]
  172. PLoS One. 2018 Oct 1;13(10):e0203941 [PMID: 30273348]
  173. Arch Microbiol. 2021 Sep;203(7):4663-4675 [PMID: 34175964]
  174. ERJ Open Res. 2020 Oct 19;6(4): [PMID: 33123558]
  175. Bioorg Med Chem Lett. 2020 Nov 1;30(21):127575 [PMID: 32980511]
  176. Antimicrob Agents Chemother. 2017 Sep 22;61(10): [PMID: 28807909]
  177. J Infect Dis. 2017 Mar 15;215(6):975-983 [PMID: 28453851]
  178. J Med Chem. 2023 Dec 14;66(23):15823-15846 [PMID: 37978953]
  179. Antimicrob Agents Chemother. 2021 Feb 17;65(3): [PMID: 33318000]
  180. Drug Deliv. 2022 Dec;29(1):2442-2458 [PMID: 35892224]
  181. Antimicrob Agents Chemother. 1994 Feb;38(2):374-7 [PMID: 8192470]
  182. Eur J Med Chem. 2022 Nov 15;242:114678 [PMID: 36037789]
  183. Infect Drug Resist. 2022 Mar 05;15:851-871 [PMID: 35281576]
  184. Antimicrob Agents Chemother. 2019 Mar 27;63(4): [PMID: 30917988]
  185. Biochem Pharmacol. 2023 Dec;218:115906 [PMID: 37951366]
  186. J Antimicrob Chemother. 2018 Sep 1;73(9):2400-2404 [PMID: 29901750]
  187. Viruses. 2022 Apr 29;14(5): [PMID: 35632679]
  188. Front Microbiol. 2022 Apr 25;13:845231 [PMID: 35547141]
  189. Int J Mol Sci. 2022 Sep 04;23(17): [PMID: 36077542]
  190. Viruses. 2021 Jan 05;13(1): [PMID: 33466377]
  191. Pharmaceuticals (Basel). 2023 Sep 25;16(10): [PMID: 37895827]
  192. Appl Microbiol Biotechnol. 2023 Dec;107(23):7119-7134 [PMID: 37755512]
  193. Pediatr Pulmonol. 2020 Nov;55(11):2990-2994 [PMID: 32662948]
  194. Virus Res. 2022 Sep;318:198856 [PMID: 35780912]
  195. Microbiol Res. 2022 Oct;263:127152 [PMID: 35944357]
  196. Antimicrob Agents Chemother. 2005 Aug;49(8):3208-16 [PMID: 16048927]
  197. Res Pharm Sci. 2018 Aug;13(4):288-303 [PMID: 30065762]
  198. Bioorg Med Chem. 2019 May 15;27(10):2090-2099 [PMID: 30975502]
  199. PLoS One. 2017 Apr 28;12(4):e0176883 [PMID: 28453568]
  200. Biomed Res Int. 2018 Jul 11;2018:9845075 [PMID: 30105271]
  201. J Microbiol Immunol Infect. 2022 Aug;55(4):708-715 [PMID: 35718718]
  202. Int J Mol Sci. 2020 Sep 01;21(17): [PMID: 32882851]
  203. Int J Mol Sci. 2021 Nov 29;22(23): [PMID: 34884695]
  204. BMC Complement Med Ther. 2023 May 24;23(1):168 [PMID: 37226152]
  205. Microorganisms. 2020 Sep 12;8(9): [PMID: 32932703]
  206. Int J Mol Sci. 2019 Apr 13;20(8): [PMID: 31013936]
  207. Children (Basel). 2022 Sep 01;9(9): [PMID: 36138639]
  208. Biofilm. 2023 Sep 16;6:100155 [PMID: 37928620]
  209. Antimicrob Agents Chemother. 2006 May;50(5):1623-7 [PMID: 16641427]
  210. Front Microbiol. 2022 Sep 15;13:979610 [PMID: 36188006]
  211. Crit Rev Microbiol. 2023 Nov 24;:1-16 [PMID: 37999716]
  212. Sci Rep. 2019 Feb 6;9(1):1527 [PMID: 30728389]
  213. Molecules. 2016 Jun 27;21(7): [PMID: 27355939]
  214. Int J Antimicrob Agents. 2021 Aug;58(2):106372 [PMID: 34116184]
  215. Antimicrob Agents Chemother. 2017 Mar 24;61(4): [PMID: 28167546]
  216. Microb Pathog. 2019 Oct;135:103623 [PMID: 31325574]
  217. Viruses. 2023 Apr 21;15(4): [PMID: 37113000]
  218. Medchemcomm. 2019 Mar 7;10(4):517-527 [PMID: 31057731]
  219. Int J Mol Sci. 2017 Jan 10;18(1): [PMID: 28075405]
  220. Eur J Pharm Sci. 2019 Dec 1;140:105058 [PMID: 31472255]
  221. Antibiotics (Basel). 2019 Jul 25;8(3): [PMID: 31349560]
  222. Adv Sci (Weinh). 2021 Jun;8(12):e2004369 [PMID: 34165899]
  223. Int J Mol Sci. 2023 Feb 02;24(3): [PMID: 36769174]
  224. Antimicrob Agents Chemother. 2001 Mar;45(3):649-59 [PMID: 11181338]
  225. Front Pharmacol. 2018 Jul 31;9:836 [PMID: 30108505]
  226. Microb Pathog. 2019 Dec;137:103770 [PMID: 31586662]
  227. NPJ Biofilms Microbiomes. 2018 Jun 29;4:13 [PMID: 29977590]
  228. Clin Microbiol Infect. 2018 May;24(5):547.e1-547.e8 [PMID: 28882728]
  229. Lett Appl Microbiol. 2022 Sep;75(3):680-688 [PMID: 35687297]
  230. Eur J Med Chem. 2022 Jun 5;236:114318 [PMID: 35398731]
  231. Front Microbiol. 2018 Jul 05;9:1349 [PMID: 30026732]

Grants

  1. FFC#6/2023/Fondazione per la Ricerca sulla Fibrosi Cistica
  2. PRIN 2020- protocol 20208LLXEJ/Ministero dell'Università e della Ricerca
Journal Article Review

Word Cloud

Created with Highcharts 10.0.0alternativeantimicrobialcysticfibrosisCFtherapiesMDRstrategiesapproachesanti-virulencecompoundsphagenewadjuvantspeptidesGram-negativepathogensPeoplesufferrecurrentbacterialinfectionsinduceinflammationlungtissuedamagefailurerespiratorysystemProlongedexposurecombinatorialantibiotictriggersappearancemulti-drugresistantbacteriadevelopmentmayprovidewaymitigateresistancediscussdifferentuseclassicantibiotics:anti-biofilmexertlowselectivepressurerepresentstrategyhightherapeuticpotentialmethodshelpingantibioticsactivitynanoparticleformulationsmechanismsvitrovivoefficacydescribedorderfigurecompletelandscapefightNewAntimicrobialStrategiesTreatMulti-DrugResistantInfectionsCausedGram-NegativesCysticFibrosisnanoparticlestherapy

Similar Articles

Cited By (4)